Stefanie Schulz-Schüpke

发表

Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents

M. Fischer, H. Schunkert, A. Kastrati, 2017, Thrombosis and Haemostasis.

Impact of design of coronary stents and length of dual antiplatelet therapies on ischaemic and bleeding events: a network meta-analysis of 64 randomized controlled trials and 102 735 patients

G. Stone, Seung‐Jung Park, A. Kastrati, 2017, European heart journal.

Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial.

H. Schunkert, A. Kastrati, J. Mehilli, 2015, Journal of the American College of Cardiology.

Duración del tratamiento antiagregante plaquetario combinado doble tras la implantación de stents farmacoactivos: el jurado continúa reunido Duration of Dual Antiplatelet Therapy After Drug-eluting Stents Implantation: The Jury Is Still Out

A. Kastrati, Stefanie Schulz-Schüpke, 2016 .

Outcomes of ≤6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation

Mario J. Garcia, S. Bangalore, P. Villablanca, 2016, Medicine.

Six Versus Twelve Months Clopidogrel Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndrome: An ISAR-SAFE Study Subgroup Analysis

M. Fischer, H. Schunkert, A. Kastrati, 2016, Scientific Reports.

Duration of Dual Antiplatelet Therapy After Drug-eluting Stents Implantation: The Jury Is Still Out.

A. Kastrati, Stefanie Schulz-Schüpke, 2015, Revista espanola de cardiologia.

Efficacy and safety of bivalirudin in coronary artery disease patients with mild to moderate chronic kidney disease: Meta-analysis.

G. Stone, Z. Jing, A. Lincoff, 2018, Journal of cardiology.

Increased bleeding risk during percutaneous coronary interventions by arterial hypertension

H. Schunkert, A. Kastrati, G. Ndrepepa, 2016, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Comparison of vascular closure devices vs manual compression after femoral artery puncture: the ISAR-CLOSURE randomized clinical trial.

C. Hengstenberg, H. Schunkert, M. Joner, 2014, JAMA.

Assessing the benefit of vascular closure devices after femoral artery puncture--reply.

A. Kastrati, Stefanie Schulz-Schüpke, 2015, JAMA.

Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2 Trials)

A. Kastrati, J. Mehilli, D. Sibbing, 2015, BioMed research international.

ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting.

Walter Desmet, Karl-Ludwig Laugwitz, Yi Li, 2015, European heart journal.

Peri- and Post-procedural Antithrombotic Therapy in Women

Stefanie Schulz-Schüpke, 2017 .

Association of progression or regression of coronary artery atherosclerosis with long-term prognosis.

H. Schunkert, A. Kastrati, G. Ndrepepa, 2016, American heart journal.

TCT-207 Extended validation of a decision tool (DAPT score) in patients randomized to 6 or 12 months dual antiplatelet therapy after percutaneous coronary intervention with predominantly second-generation drug-eluting stents.

A. Kastrati, Y. Harada, J. Michel, 2016, Journal of the American College of Cardiology.

Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis: 3-Year Results of a Randomized Controlled Trial.

H. Schunkert, A. Kastrati, F. Neumann, 2015, JACC. Cardiovascular interventions.

Comparison of vascular closure devices vs manual compression after femoral artery puncture: the ISAR-CLOSURE randomized clinical trial.

C. Hengstenberg, H. Schunkert, M. Joner, 2014, JAMA.

Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents

M. Fischer, H. Schunkert, A. Kastrati, 2017, Thrombosis and Haemostasis.

Long-Term Ef fi cacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis 3-Year Results of a Randomized Controlled Trial

H. Schunkert, A. Kastrati, F. Neumann, 2022 .